

Index

Note: page numbers in *italics* refer to *figures*.

- acceptance and commitment therapy (ACT)
 - 90–91
- activity pacing 89–90
- acupuncture 74, 77–78, 78
- acute pain 1
 - assessment 31
 - chronic pain vs. 2–3
 - nerve blockade 44, 44
 - non-opioid analgesics 51
 - outcomes 42–43, 43
 - psychological interventions 85–86
- addiction, opioid 55–57
- adjuvant analgesics 39–40, 40, 45
- allodynia 4
- analgesia, regional 43–45
 - see also* local anaesthetics; nerve blocks
- analgesic ladder, WHO 38, 38–39, 49, 50
- analgesics
 - adjuvant 39–40, 40, 45
 - children 47
 - combination therapy 42
 - drug delivery methods 43–45
 - elderly patients 47, 69–70
 - general principles 37–38
 - neuropathic pain 65–69
 - neuropathic vs. nociceptive pain 42
 - non-opioid 50–54, 51
 - opioid *see* opioid analgesics
 - pregnancy/lactation 69
 - see also individual drugs*
- anterior cingulate cortex (ACC) 15, 16
- anticonvulsants 40, 40, 65, 66, 67–68, 69
- antidepressants 40, 40, 45, 65, 65–67, 69
- arachidonic acid 52, 53, 53
- aspartate 13
- assessment, patient 25–35, 28, 29
- autonomic ganglion blocks 75–76
- back pain, chronic
 - assessment 32, 34
 - cortical reorganization 21
 - idiopathic 7
 - 'red flags' 31, 31
 - 'yellow flags' 29–30, 30, 86, 86
- baclofen 81
- biopsychosocial model of pain 25, 26, 84, 85, 85
- bradykinin 12
- Brief Pain Inventory 27
- buprenorphine 38, 62, 64
- CAGE questionnaire 30
- cancer pain 3, 31, 38, 46–47
- cannabinoids 18, 69
- capsaicin 20, 40, 45, 69
- carbamazepine 40, 45, 65, 67
- categorical pain rating scales 26, 26
- celecoxib 52, 53
- central sensitization 19, 21, 22, 23, 68
- CGRP (calcitonin gene-related peptide) 13
- chemical neuroablation 82–83
- chemical neuromodulation 81
- children 47
 - FACES pain scale 26, 26
- cholecystokinin (CCK) 18, 56
- chronic pain 2
 - acute pain vs. 2–3
 - assessment 31–35
 - back *see* back pain, chronic
 - early intervention 42–43
 - measurement 27
 - nerve blockade 44, 44
 - non-pharmacological management 44–46, 73–91
 - opioid selection and recommendations 63–64
 - psychosocial predictors 28–30, 86, 86
 - treatment of comorbidities 46
- CNS response to injury 22, 22, 23

- codeine 38, 39, 41, 57, 64
cognitive-behavioural therapy 84, 88, 90
combination pain 4, 4
combination therapy 42, 49
complex regional pain syndrome 32, 88
cortical reorganization 21, 21
counterstimulation 74, 77–80
cryoanalgesia 82
cyclo-oxygenase 39, 50, 53, 54
cyclo-oxygenase-2 inhibitors (COXIBs) 38, 39, 50, 52, 53
- definitions 1, 2–4, 21
dependence, opioid 55, 56
depression 1, 2, 29, 30, 46, 67
 psychogenic pain 6
dextropropoxyphene 38, 39, 41, 58
diagnostic nerve blocks 73–76
diagnostic testing 33–34
diclofenac 39, 41, 51, 52, 52
dihydrocodeine 38, 39, 41, 57
dorsal horn 15
 activation-dependent plasticity 19
 anatomy 10–13, 12
 ascending tracts 13–15, 14
 central sensitization 22, 23
 descending inhibition 17–19
 endogenous opioid action 16–17, 15
 neurotransmitters 13, 18
 opioid receptors 16–17, 17, 23
 pain modulation 15–19
 segmental inhibition 17, 18
 transcriptional changes 19, 21
drug delivery 43–45
DSM-IV criteria 6, 55, 56
dynorphins 16, 17, 56
dysaesthesiae 4
- elderly patients 47, 54, 69–70
electromyography (EMG) 34
 biofeedback 88
endogenous opioids 15, 16–17, 17, 18, 54
endorphins 16, 17, 18, 54
enkephalins 16, 17, 18
epidural blockade 44, 44, 74
epidural steroid injections 74–75
etoricoxib 52, 53
excitatory nociceptive transmission 13
exercise 89
- FACES pain scale 26, 26
facet joint 34, 74, 77, 82
 injections 77
fear, pain-related 87, 87
- fentanyl 38, 42, 52, 54, 62–63, 64
fibromyalgia syndrome 21, 32, 78
- GABA (gamma-aminobutyric acid) 17, 18, 23
gabapentin 40, 42, 45, 65, 66, 67
galanin 18
gate control theory 16, 17, 18, 84
glutamate 13
glycine 17, 18
- histamine 12, 59, 61
5-HT (serotonin) 12, 18, 19
hydromorphone 38, 60, 64
hyperaesthesia 4
hyperalgesia 3–4, 19, 20
hyperpathia 4
- ibuprofen 39, 41, 51, 52, 52
‘idiopathic pain’ 7
injections 20, 43–44, 74, 76–77
integrated care pathways (ICPs) 37
International Association for the Study of Pain
 definition of neuropathic pain 21
 definition of pain 1
intrathecal drug delivery (ITDD) 74, 81
invasive procedures 73–83, 74
- joint injections 74, 77
- ketamine 45, 65, 68–69
- lactation 69
lamotrigine 40, 45, 68
Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) 28, 29
leukotrienes 12, 53, 53
lidocaine 40, 45, 65, 68
limb amputation 21, 21
local anaesthetics 44–45, 66, 68, 81
lumiracoxib 52, 53
- magnetic resonance imaging (MRI) 15, 34
McGill Pain Questionnaire 27
meridians (acupuncture) 77, 78
methadone 38, 62, 63, 64
mexiletine 68
mirror box 88, 89
modulation, pain 9, 15–19
molar tooth extraction 41
morphine 17, 54, 57, 58–60
 combination therapy 42
 equi-analgesic doses 63, 64
 intrathecal delivery 81
 neuropathic pain 42

- PAG–RVM system (periaqueductal grey matter–rostral ventromedial medulla system) 19
- patient-controlled analgesia 59–60, 61
tolerance 69
- WHO analgesic ladder 38
- multidisciplinary pain management programmes 90–91
- multimodal analgesia 42, 49
- musculoskeletal pain 31–32, 34
- myofascial pain syndrome 32, 77, 78
- naproxen 39, 41, 52, 52
- neospinothalamic tract 13, 14
- nerve blocks 20, 44–45, 73–76, 74
- nerve conduction velocity (NCV) studies 34
- nerve injury 22, 22–23
- neuroablative procedures 74, 81–83
- neurological assessment 32, 33
- neurolytic agents 82–83
- neurolytic block 45
- neuromodulation techniques 74, 80–81
- neuropathic damage 6
- neuropathic pain 5–6
adjuvant analgesics 39, 40
analgesics 65, 65–69, 66
assessment 27–28, 29, 34
definition 21
features 29
mechanisms 21–23, 22
nociceptive pain vs. 28, 29, 42
opioids 42
plasticity 19
- neuropathic pain ladder 65, 66
- Neuropathic Pain Scale (NPS) 28
- neuropeptides 12, 13
see also individual neuropeptides
- neurotransmitters, dorsal horn 13, 17, 18, 19
- nitric oxide 18, 51
- NMDA (*N*-methyl-*D*-aspartate)
antagonists 40, 45, 45, 65, 65, 66, 68–69
receptor 13, 19, 65, 68
- nociception 9
- nociceptive pain 4–5
assessment 27
features 28
neuropathic pain vs. 28, 29, 42
somatic 4–5, 27, 28
visceral 5, 10, 27, 28
- nociceptors 9–10, 10, 11, 12
- non-malignant pain
neuromodulatory techniques 80
opioids 30, 30, 39, 64
- non-opioid analgesics 50–54, 51
- non-pharmacological interventions 43–46, 73–91
- non-steroidal anti-inflammatory drugs (NSAIDs) 38, 38, 39, 52, 52–54
opioids vs., pain relief following molar tooth extraction 41
in pregnancy 69
- norepinephrine (noradrenaline) 18, 19, 76
- numerical pain rating scales 27
- operant techniques 87
- opioid addiction 55–57
- opioid analgesics 54–64
chronic pain, selection and recommendations 63–64
equi-analgesic doses 63, 64
neuropathic pain 42
non-malignant pain 30, 30, 39, 64
NSAIDs vs., pain relief following molar tooth extraction 41
in pregnancy 69
Step 2 and 3 39
strong 58–64
weak 57–58
- opioid dependence 55, 56
- opioid receptors 16–17, 17, 18, 19, 23, 54
- opioids, endogenous 15, 16–17, 18, 54
- opioid tolerance 55, 68
- orthopaedic examination 32
- osteoarthritis 4, 33, 34, 51, 78, 80
- oxycodone 38, 41, 42, 54, 60–61, 64
- PAG–RVM system (periaqueductal grey matter–rostral ventromedial medulla system) 18–19
- pain
anatomy and physiology 9–24
biopsychosocial model 25, 26, 84, 85, 85
clinical classification 4–7
definitions 1, 2–4, 21
effects of 1, 1–2, 2
modulation 9, 15–19
patient evaluation 25–35
perception 15, 16
plasticity 9, 19, 21
quality of life and 1–2
scales 25–27
threshold 3
tolerance 3
transduction 9–10, 10, 11, 12
transmission 10–15
- pain management
integrated care pathways 37
multidisciplinary programmes 90–91
non-pharmacological 43–46, 73–91

- overview of options 37–48
 - pharmacological 42–43, 49–70
 - treatment of comorbidities 46
 - see also* analgesics
 - pain-related fear 87, 87
 - paleospinothalamic tract 13, 14
 - parabrachial pathway 15
 - paracetamol 38, 41, 51, 51–52, 57, 58, 69
 - paraesthesiae 4
 - patient-controlled analgesia (PCA) 60
 - children 47
 - elderly patients 47
 - fentanyl 63
 - morphine 59–60, 61
 - tramadol 58
 - patient evaluation 25–35, 28, 29
 - PCA *see* patient-controlled analgesia
 - perception, pain 15, 16
 - periaqueductal grey matter 13, 14, 18
 - peripheral nerve blocks 75, 75
 - peripheral nerve stimulation (PNS) 74, 81
 - phantom limb pain 88
 - pharmacotherapy 49–72
 - see also* analgesics
 - phenazone (antipyrine) 52
 - physical neuromodulation 80–81
 - physical therapy 45–46, 78–79
 - plasticity 9, 19, 21
 - polymodal nociceptors 10
 - position emission tomography (PET) 15
 - postoperative pain 44, 85–86
 - potassium 12
 - pregabalin 40, 45, 65, 67
 - pregnancy 69
 - primary afferent conduction 10
 - primary afferent pain fibres 9–10, 10, 11, 12, 12–13
 - prostaglandins 12, 52, 53, 53
 - psychogenic pain 6
 - psychological approaches 46, 84–86, 87–89
 - psychosocial predictors 28–30, 86, 86
- quality of life, pain and 1–2
- radiofrequency (RF) ablation 82
 - 'red flags' 31, 31
 - referred pain 5, 13, 23
 - regional analgesia 43–45
 - see also* local anaesthetics; nerve blocks
 - rehabilitative approaches 89–90
 - respondent techniques 87, 88
 - Rexed's laminae 10, 12
 - rheumatoid arthritis 4, 4, 38
 - rostral ventromedial medulla (RVM) 18
 - sacroiliac joint 32, 76
 - scales, pain 25–27
 - selective serotonin reuptake inhibitors (SSRIs) 40, 45, 65, 65, 67
 - serotonin (5-HT) 12, 18, 19
 - serotonin and noradrenaline reuptake inhibitors (SNRIs) 40, 45, 65, 65, 67
 - Short-Form McGill Pain Questionnaire 27
 - skeletal muscle pain, assessment 31–32
 - sodium valproate 40, 45, 65, 68
 - somatic pain 4–5, 27, 28
 - somatoform disorders, psychogenic pain 6
 - spinal blockade 44, 44
 - spinal cord stimulation (SCS) 17, 74, 80–81
 - spinomesencephalic tract 15
 - spinoreticular tract 15
 - spinothalamic tracts 13–14, 14
 - strong opioids 58–64
 - substance P 12, 13, 22
 - surgical neuroablation 83
 - sympathetic nerve blocks 75–76
 - sympathetic nerves and ganglia 76
- TENS (transcutaneous electrical nerve stimulation) 17, 74, 79, 79–80
- thermal neuroablation 82
 - threshold, pain 3
 - thromboxanes 53, 53
 - tolerance
 - opioid 55, 68
 - pain 3
 - tramadol 19, 41, 58
 - equi-analgesic doses 64
 - neuropathic pain 40, 42, 45, 63
 - in pregnancy 69
 - WHO analgesic ladder 38
 - transcriptional changes, dorsal horn 19, 21
 - transduction, pain 9–10, 10, 11, 12
 - transmission, pain 10–15
 - tricyclic antidepressants (TCAs) 65, 66, 66
 - trigger points and injections 32, 74, 77
- valproate, sodium 40, 45, 65, 68
 - vertebroplasty 83, 83
 - visceral pain 5, 10, 27, 28
 - visual analogue scales 25
- weak opioids 57–58
 - WHO analgesic ladder 38, 38–39, 49, 50
 - 'wind-up' phenomenon 19, 23, 68
 - Wong–Baker FACES pain rating scale 26
 - 'yellow flags' 29–30, 30, 86, 86